Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage

Annamaria Colao, Antonella Di Sarno, Maria Luisa Landi, Sossio Cirillo, Francesca Sarnacchiaro, Giuseppina Facciolli, Rosario Pivonello, Mauro Cataldi, Bartolomero Merola, Lucio Annunziato, Gaetano Lombardi
1998 Obstetrical and Gynecological Survey  
Cabergoline (CAB), a long-lasting dopamine-agonist, specific for the D 2 receptor, is effective in normalizing serum PRL levels in most patients with microprolactinoma or idiopathic hyperprolactinemia. Because few data are presently available on the effects of CAB treatment in macroprolactinomas, the aim of this open-label study was to investigate whether this drug was effective in producing tumor shrinkage, as well as in normalizing PRL levels. Twenty-three patients with macroprolactinoma
more » ... ed this study: 15 patients had had no treatment, whereas the remaining 8 patients had been previously treated with bromocriptine, which was withdrawn because of intolerance. Three of 23 patients had undergone unsuccessful surgery. Pretreatment serum PRL levels ranged from 100-3860 g/L. CAB was administered at a dose of 0.5-3 mg once or twice a week for 12-24 months. Magnetic resonance imaging (MRI) scans were performed before and 3, 6, 12, and 24 months after the beginning of treatment, to evaluate tumor shrinkage, defined as a decrease of at least 80% of baseline tumor volume. After 3-6 months of treatment with a low dose (0.5-1 mg/week), serum PRL levels normalized in 18 patients. In the remaining 5 patients, whose serum PRL levels were not normalized, the dose was
doi:10.1097/00006254-199805000-00017 fatcat:25hh4ynbprh6nmzo6htxs52tkm